Skip to main content

Table 1 Patient and donor characteristics

From: HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level

Patient characteristics

Patients (n/%)

DSA negative

DSA positive

P-value

Total patient numbers

430

349 (81.2)

81 (18.8)

Age of recipient, years

50 (1–68)

50 (1–68)

49 (1–63)

0.156

BMI of recipient, kg/m2

24 (10.0–55.0)

24.5 (10.0–55.0)

24.2 (10–32.5)

0.306

Weight of recipient, kg

72 (36–157)

73 (36–157)

70 (43–103)

0.022

MELD

17 (6–40)

17 (6–40)

17.5 (6–40)

0.940

Cold ischemia time, h

7:14 (1:01–20:00)

7:14 (1:01–18:10)

7:14 (1:15–20:00)

0.363

Sex, m/f (%)

252 (59)/178 (41)

211 (60.5)/138 (39.5)

41 (50.6)/40 (49.4)

0.133

Donor characteristics

 Total donor numbers

377

 Age of donor, years

51 (2–88)

51 (2–88)

49 (3–82)

0.171

 BMI of donor, kg/m2

25.0 (11.0–51.0)

25 (11–51)

25 (10.3–36)

0.236

 Weight of donor, kg

75 (12–170)

75 (12–160)

75 (17–170)

0.316

 Sex D/R: f + f; m + m/f + m; m + f

232 (61.5)/145 (38.5)

194 (83.6)/111 (76.6)

38 (16.4)/34 (23.4)

0.106

Indication for LT

 HCV

102 (23.7)

86 (24.6)

16 (19.8)

0.387

 ASH

95 (22.1)

87 (24.9)

8 (9.9)

0.003

 HCC

91 (21.2)

83 (23.8)

8 (9.9)

0.006

 HBV

70 (16.3)

56 (16.0)

14 (17.3)

0.741

 NASH

69 (16.0)

57 (16.3)

12 (14.8(

0.867

 PSC/PBC/AIH (AIL)

64 (14.9)

46 (13.2)

18 (22.2)

0.055

 Acute liver failure

32 (7.4)

23 (6.6)

9 (11.1)

0.163

 Other

29 (6.7)

26 (7.4)

3 (3.7)

0.325

  1. Patient characteristics given as median and range and etiology of liver disease (n/%)
  2. AIH autoimmune hepatitis, AIL autoimmune liver disease, ASH alcoholic steatohepatitis, BMI body mass index, D donor, DSA donor specific antibody, f female, HBV hepatitis B, HCV hepatitis C, LT liver transplant, m male, MELD model of end stage liver disease, NASH nonalcoholic steatohepatitis, PBC Primary biliary cholangitis, PSC primary sclerosing cholangitis, R recipient